A case of topical imiquimod induced fatigue. (17th November 2022)

• Record Type: Journal Article
• Authors: Raman, Justin; Bisbee, Elizabeth; Missall, Tricia A.; Saikaly, Sami K.
• Is Part Of: Journal of dermatological treatment. Volume 33:Number 8(2022)
• Page Start: 3202
• Page End: 3204
• Publication Date: 2022-11-17
• Subjects: Imiquimod -- fatigue -- drug reaction -- melanoma; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2022.2125266
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Topical imiquimod is used for a variety of common dermatologic lesions, including melanoma in-situ . As an immunomodulator, it is relatively well tolerated with minimal side effects, including scaling, erythema, and edema. Here we present a rare systemic adverse effect, where our patient experienced debilitating severe fatigue when applying imiquimod to a single lesion. Clinicians should be mindful of this side effect and counsel patients appropriately.